Business Wire

MA-EVERBRIDGE

Share
Dr. Anthony Fauci Joined by C-Level Executives from IBM, Goldman Sachs, Carlyle Group, Mayo Clinic, and Ford, as well as Gov. of Mississippi and Miami Mayor, to Present at Everbridge’s Symposium, COVID-19: Road to Recovery, Oct. 14-15, 2020

Everbridge , Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM ), today announced additional top-tier Fortune 50 C-level executives, government officials and healthcare experts who have joined as speakers for its Autumn 2020 “COVID-19 R2R: The Road to Recovery” virtual leadership summit to be held October 14-15, 2020, covering the path forward amid COVID-19.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201006006062/en/

The latest speakers to join the Symposium include: retired Ford Motor Company Chief Executive Officer Jim Hackett, IBM President Jim Whitehurst, Mayo Clinic Platform Chief Medical Officer Clark C. Otley, M.D., Kaiser Permanente Associate Executive Director Stephen Parodi, MD, Los Angeles World Airports (LAWA) Chief Executive Officer Justin Erbacci, Goldman Sachs Chief Information Officer George Lee, Carlyle Group (CAG Holdings) Chief Strategy Officer Ginger Evans, Mississippi Governor Tate Reeves, Former Lieutenant Governor of Florida Carlos Lopez-Cantera, and Miami Mayor Francis Suarez. The event will also feature Gaurdie Banister, former President and CEO, Aera Energy LLC and Corporate Director of DOW, Russell Reynolds Associates, and Tyson Foods .

Each of these top speakers brings significant leadership experience managing some of the world’s largest and most iconic organizations, healthcare institutions and governments through the coronavirus pandemic and will cover topics related to global best practices to reopen economies, while most safely returning people to public spaces, offices, and campuses.

In addition to these top speakers, the two-day symposium will feature a former World Head of State , presidential advisor and Director of the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health (NIH) Dr. Anthony Fauci , Virgin Group Founder Sir Richard Branson , and renowned neurosurgeon and CNN Chief Medical Correspondent Dr. Sanjay Gupta , as well as sessions with leading healthcare experts and government officials.

To attend the “COVID-19 R2R: The Road to Recovery” virtual leadership summit, please visit Everbridge’s event registration page .

“Everbridge provides key insights that public and private sector leaders need right now to navigate this next crucial phase of the coronavirus pandemic, to reopen economies while most safely returning people to public spaces, offices and campuses,” said Everbridge Chief Executive Officer David Meredith. “By leveraging our global partner and customer ecosystem, Everbridge continues to add top C-level leaders to our speaker lineup, as well as marquee keynotes including Dr. Anthony Fauci, Sir Richard Branson, Dr. Sanjay Gupta, and a former World Leader. While our most recent COVID-19 Symposium attracted well over 10,000 leaders across 150 countries, our current registrations remain on track to far exceed those numbers.”

The symposium will focus on the policies and actions organizations can take during the pandemic to keep people safe, execute contact tracing, return people to workplaces, campuses, and public spaces, protect supply chains, restore operations, and help organizations manage their reputations and communications to foster consumer safety and trust; all while managing across multiple critical events that could include hurricanes, wildfires, production stoppages, IT outages and cyberattacks.

To see a current list of speakers and register for the event, please visit here . Beyond the latest additions announced today, representative C-level speakers from Fortune 500 and international corporations also include a Fortune 25 Chief Executive Officer (CEO), Fortinet Founder, Chairman of the Board, and CEO Ken Xie, Accenture’s Arlin Pedrick, Auburn University’s President Jay Gogue, Aviva’s John Bernard, CAG Holdings’ Ginger Evans, Capital One’s William Baker, Fannie Mae’s Christopher Porter, Humana’s Stephan Pazienza, Lumen Technologies’ (formerly CenturyLink) Executive Vice President of Human Resources Scott Trezise, Optum’s Allison Miller, Rackspace Chief Legal and People Officer Holly Windham, and Siemens ’ Marco Mille, among others.

Speakers representing the healthcare and government sectors include Roberta Levy Schwartz, Ph.D., FACHE, Executive Vice President and Chief Innovation Officer at Houston Methodist and CEO of Houston Methodist Hospital ; Dr. Judy Monroe, Chief Executive Officer of the CDC Foundation ; Dr. Nancy Messonnier, Director of the Center for the National Center for Immunization and Respiratory Diseases (NCIRD ); Matt Roman, Chief Digital Strategy Officer of Duke University Health System ; Curt Wood, Chief Information Officer of the Commonwealth of Massachusetts ; Rebecca Baudendistel, Director of Public Warning at New York City Emergency Management Department ; Víðir Reynisson, Chief Superintendent of the Office of National Commission of Police in Iceland ; Benoît Vivier, European Union institutions liaison at the European Emergency Number Association (EENA) ; and Michael Hallowes, former National Director of Australia’s Emergency Alert program and Managing Director of Zefonar .

Over 5,300 global organizations use Everbridge’s CEM Platform to assess threats, monitor the wellbeing of their workforce, rapidly communicate warnings, and protect supply chains. At the onset of the pandemic, Everbridge rapidly launched its COVID-19 Shield™ Return to Work and Contact Tracing software solutions followed by the introduction of Everbridge Control Center , the industry’s first off-the-shelf physical security information management software platform to help organizations return to work while complying with social distancing and Personal Protective Equipment (PPE) policies. Since the pandemic began, Everbridge customers have used its software to send more than 780 million coronavirus-related communications with vital information and instructions to safeguard their populations, employees, patients, and students.

Everbridge serves over 3,700 first responder agencies and 1,500 healthcare entities including the top pharmaceutical, biomedical and medical device and manufacturing companies, as well as the largest healthcare systems (overseeing more than 25 percent of all hospital beds in the U.S.), managed care organizations, pharmacies, and statewide health alert networks (HANs), including the CDC and the NIH.

The Everbridge Platform reaches over 600 million people and currently supports the countrywide public warning system deployments in all major regions of the world . Everbridge supports population-wide alerting in 11 countries across Europe, Asia, Oceania, The Middle East, Africa, and South America including Australia , Iceland , the Netherlands, New Zealand, Norway , Peru , Singapore and Sweden . Everbridge’s population alerting capabilities also power the entire states of California , Massachusetts , Vermont , New York , Connecticut , and Florida , as well as municipalities, counties and cities within 49 of the 50 United States, within all of Canada’s provinces, and throughout Europe and Asia, including deployments within multiple populous states in India .

About Everbridge

Everbridge, Inc. (NASDAQ: EVBG) is a global software company that provides enterprise software applications that automate and accelerate organizations’ operational response to critical events in order Keep People Safe and Businesses Running™. During public safety threats such as active shooter situations, terrorist attacks or severe weather conditions, as well as critical business events including IT outages, cyber-attacks or other incidents such as product recalls or supply-chain interruptions, over 5,300 global customers rely on the Company’s Critical Event Management Platform to quickly and reliably aggregate and assess threat data, locate people at risk and responders able to assist, automate the execution of pre-defined communications processes through the secure delivery to over 100 different communication devices, and track progress on executing response plans. Everbridge serves 8 of the 10 largest U.S. cities, 9 of the 10 largest U.S.-based investment banks, 47 of the 50 busiest North American airports, 9 of the 10 largest global consulting firms, 8 of the 10 largest global automakers, 9 of the 10 largest U.S.-based health care providers, and 7 of the 10 largest technology companies in the world. Everbridge is based in Boston with additional offices in 14 cities around the globe. For more information visit www.everbridge.com

Cautionary Language Concerning Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the anticipated opportunity and trends for growth in our critical communications and enterprise safety applications and our overall business, our market opportunity, our expectations regarding sales of our products, our goal to maintain market leadership and extend the markets in which we compete for customers, and anticipated impact on financial results. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “expect,” “anticipate,” “should,” “believe,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,” variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the ability of our products and services to perform as intended and meet our customers’ expectations; our ability to successfully integrate businesses and assets that we may acquire; our ability to attract new customers and retain and increase sales to existing customers; our ability to increase sales of our Mass Notification application and/or ability to increase sales of our other applications; developments in the market for targeted and contextually relevant critical communications or the associated regulatory environment; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we have not been profitable on a consistent basis historically and may not achieve or maintain profitability in the future; the lengthy and unpredictable sales cycles for new customers; nature of our business exposes us to inherent liability risks; our ability to attract, integrate and retain qualified personnel; our ability to maintain successful relationships with our channel partners and technology partners; our ability to manage our growth effectively; our ability to respond to competitive pressures; potential liability related to privacy and security of personally identifiable information; our ability to protect our intellectual property rights, and the other risks detailed in our risk factors discussed in filings with the U.S. Securities and Exchange Commission (“SEC”), including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on February 28, 2020. The forward-looking statements included in this press release represent our views as of the date of this press release. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

All Everbridge products are trademarks of Everbridge, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye